Novo Nordisk Q4 Preview: Rybelsus’s Launch Key Focus
Analysts Expect Strong Q4 GLP-1 Volumes Offset By US Pricing Pressures
Ozempic's continued good growth and the ongoing roll out of oral Rybelsus should revitalize growth and expand Novo's reach in the diabetes market this year.
You may also be interested in...
Novo Nordisk’s semaglutide, a GLP-1 agonist marketed in an injected formulation as Ozempic, and an oral tablet form as Rybelsus, is a success story with the potential for an epic third act. First approved as a treatment for type 2 diabetes, semaglutide is under FDA review as a treatment for obesity, with additional clinical programs in NASH and Alzheimer’s disease.
Alnylam’s Givlaari for acute hepatic porphyria is also among the 14 new products that could get an EU approval recommendation this week.
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.